272 related articles for article (PubMed ID: 34652632)
61. Novel ABCD1 gene mutations in Iranian pedigrees with X-linked adrenoleukodystrophy.
Emamalizadeh B; Daneshmandpour Y; Tafakhori A; Ranji-Burachaloo S; Shafiee S; Ghods E; Darvish H
J Pediatr Endocrinol Metab; 2019 Nov; 32(11):1207-1215. PubMed ID: 31665121
[TBL] [Abstract][Full Text] [Related]
62. Epigenomic signature of adrenoleukodystrophy predicts compromised oligodendrocyte differentiation.
Schlüter A; Sandoval J; Fourcade S; Díaz-Lagares A; Ruiz M; Casaccia P; Esteller M; Pujol A
Brain Pathol; 2018 Nov; 28(6):902-919. PubMed ID: 29476661
[TBL] [Abstract][Full Text] [Related]
63. X-linked adrenoleukodystrophy in a chimpanzee due to an ABCD1 mutation reported in multiple unrelated humans.
Curiel J; Steinberg SJ; Bright S; Snowden A; Moser AB; Eichler F; Dubbs HA; Hacia JG; Ely JJ; Bezner J; Gean A; Vanderver A
Mol Genet Metab; 2017 Nov; 122(3):130-133. PubMed ID: 28919002
[TBL] [Abstract][Full Text] [Related]
64. X-linked adrenoleukodystrophy caused by a novel mutation presenting with various phenotypes in a Taiwanese family.
Chien CY; Chang KH; Chen CM
Clin Chim Acta; 2021 Mar; 514():100-106. PubMed ID: 33359056
[TBL] [Abstract][Full Text] [Related]
65. Differing clinical presentations of two unrelated cases of X-linked adrenoleukodystrophy with identical mutation Y296C in the ABCD1 gene.
Sutovský S; Kolníková M; Petrovic R; Kollár B; Siarnik P; Chandoga J; Fischerová M; Turcáni P
Neuro Endocrinol Lett; 2014; 35(5):411-6. PubMed ID: 25275259
[TBL] [Abstract][Full Text] [Related]
66. Caffeic acid phenethyl ester induces adrenoleukodystrophy (Abcd2) gene in human X-ALD fibroblasts and inhibits the proinflammatory response in Abcd1/2 silenced mouse primary astrocytes.
Singh J; Khan M; Singh I
Biochim Biophys Acta; 2013 Apr; 1831(4):747-58. PubMed ID: 23318275
[TBL] [Abstract][Full Text] [Related]
67. Phenotypic variability in a family with x-linked adrenoleukodystrophy caused by the p.Trp132Ter mutation.
Soardi FC; Esquiaveto-Aun AM; Guerra-Júnior G; Lemos-Marini SH; Mello MP
Arq Bras Endocrinol Metabol; 2010 Nov; 54(8):738-43. PubMed ID: 21340162
[TBL] [Abstract][Full Text] [Related]
68. HDAC inhibitor SAHA normalizes the levels of VLCFAs in human skin fibroblasts from X-ALD patients and downregulates the expression of proinflammatory cytokines in Abcd1/2-silenced mouse astrocytes.
Singh J; Khan M; Singh I
J Lipid Res; 2011 Nov; 52(11):2056-69. PubMed ID: 21891797
[TBL] [Abstract][Full Text] [Related]
69. Dementia from the ABCD1 mutation c.1415-1416delAG in a female carrier.
Finsterer J; Lässer S; Stöphasius E
Gene; 2013 Nov; 530(1):155-7. PubMed ID: 23962690
[TBL] [Abstract][Full Text] [Related]
70. X-linked adrenoleukodystrophy: very long-chain fatty acid metabolism is severely impaired in monocytes but not in lymphocytes.
Weber FD; Wiesinger C; Forss-Petter S; Regelsberger G; Einwich A; Weber WH; Köhler W; Stockinger H; Berger J
Hum Mol Genet; 2014 May; 23(10):2542-50. PubMed ID: 24363066
[TBL] [Abstract][Full Text] [Related]
71. Role of ALDP (ABCD1) and mitochondria in X-linked adrenoleukodystrophy.
McGuinness MC; Lu JF; Zhang HP; Dong GX; Heinzer AK; Watkins PA; Powers J; Smith KD
Mol Cell Biol; 2003 Jan; 23(2):744-53. PubMed ID: 12509471
[TBL] [Abstract][Full Text] [Related]
72. Biochemical aspects of X-linked adrenoleukodystrophy.
Kemp S; Wanders R
Brain Pathol; 2010 Jul; 20(4):831-7. PubMed ID: 20626744
[TBL] [Abstract][Full Text] [Related]
73. Biochemical Studies in Fibroblasts to Interpret Variants of Unknown Significance in the
van de Stadt SIW; Mooyer PAW; Dijkstra IME; Dekker CJM; Vats D; Vera M; Ruzhnikov MRZ; van Haren K; Tang N; Koop K; Willemsen MA; Hui J; Vaz FM; Ebberink MS; Engelen M; Kemp S; Ferdinandusse S
Genes (Basel); 2021 Nov; 12(12):. PubMed ID: 34946879
[TBL] [Abstract][Full Text] [Related]
74. Targeted inactivation of the X-linked adrenoleukodystrophy gene in mice.
Forss-Petter S; Werner H; Berger J; Lassmann H; Molzer B; Schwab MH; Bernheimer H; Zimmermann F; Nave KA
J Neurosci Res; 1997 Dec; 50(5):829-43. PubMed ID: 9418970
[TBL] [Abstract][Full Text] [Related]
75. [Overview of X-linked adrenoleukodystrophy in Morocco: results of the implementation of the program of clinical and biological diagnosis].
Benjelloun FM; Chabraoui L; Kriouile Y
Pan Afr Med J; 2017; 28():185. PubMed ID: 29599883
[TBL] [Abstract][Full Text] [Related]
76. Endocrine Dysfunction in X-Linked Adrenoleukodystrophy.
Burtman E; Regelmann MO
Endocrinol Metab Clin North Am; 2016 Jun; 45(2):295-309. PubMed ID: 27241966
[TBL] [Abstract][Full Text] [Related]
77. X-linked adrenoleukodystrophy: ABCD1 de novo mutations and mosaicism.
Wang Y; Busin R; Reeves C; Bezman L; Raymond G; Toomer CJ; Watkins PA; Snowden A; Moser A; Naidu S; Bibat G; Hewson S; Tam K; Clarke JT; Charnas L; Stetten G; Karczeski B; Cutting G; Steinberg S
Mol Genet Metab; 2011; 104(1-2):160-6. PubMed ID: 21700483
[TBL] [Abstract][Full Text] [Related]
78. Phenotypic variability in a Tunisian family with X-linked adrenoleukodystrophy caused by the p.Gln316Pro novel mutation.
Kallabi F; Ellouz E; Tabebi M; Ben Salah G; Kaabechi N; Keskes L; Triki C; Kamoun H
Clin Chim Acta; 2016 Jan; 453():141-6. PubMed ID: 26686776
[TBL] [Abstract][Full Text] [Related]
79. [Clinical characteristics of X-linked adrenoleukodystrophy].
Xiong H; Zhang YH; Qin J; Xiao JX; Shi CY; Zhou SM; Wu XR
Zhonghua Er Ke Za Zhi; 2003 Mar; 41(3):203-7. PubMed ID: 14756960
[TBL] [Abstract][Full Text] [Related]
80. Comparison of C26:0-carnitine and C26:0-lysophosphatidylcholine as diagnostic markers in dried blood spots from newborns and patients with adrenoleukodystrophy.
Huffnagel IC; van de Beek MC; Showers AL; Orsini JJ; Klouwer FCC; Dijkstra IME; Schielen PC; van Lenthe H; Wanders RJA; Vaz FM; Morrissey MA; Engelen M; Kemp S
Mol Genet Metab; 2017 Dec; 122(4):209-215. PubMed ID: 29089175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
